Literature DB >> 7680662

Posttranslational regulation of insulin-like growth factor binding protein-4 in normal and transformed human fibroblasts. Insulin-like growth factor dependence and biological studies.

C A Conover1, M C Kiefer, J Zapf.   

Abstract

Insulin-like growth factor binding protein-4 (IGFBP-4) is a 24-26-kD protein expressed by a variety of cell types in vivo and in vitro. Treatment of normal adult human fibroblasts with 10 nM insulin-like growth factor II (IGF-II) for 24 h resulted in an 85% decrease in endogenous IGFBP-4, as assessed by Western ligand blot analysis of the conditioned medium. Incubation of human fibroblast-conditioned medium (HFCM) with IGF-II under cell-free conditions led to a similar loss of IGFBP-4. This posttranslationally regulated decrease in IGFBP-4 appeared to be due to a protease in HFCM: (a) It could be prevented with specific protease inhibitors or incubation at 4 degrees C; (b) proteolysis of recombinant human (rh) IGFBP-4 required HFCM; (c) immunoblotting and radiolabeling confirmed cleavage of IGFBP-4 into 18- and 14-kD IGFBP-4 fragments. The protease was specific for IGFBP-4, and was strictly dependent on IGFs for activation. IGF-II was the most effective of the natural and mutant IGFs tested, inducing complete hydrolysis of rhIGFBP-4 at a molar ratio of 0.25:1 (IGF/IGFBP-4). Simian virus 40-transformed adult human fibroblasts also expressed IGFBP-4 and IGFBP-4 protease, as well as an inhibitor of IGFBP-4 proteolysis. In biological studies, intact rhIGFBP-4 potently inhibited IGF-I-stimulated [3H]aminoisobutyric acid uptake, whereas proteolyzed rhIGFBP-4 had no inhibitory effect. In conclusion, these data provide evidence for a novel IGF-dependent IGFBP-4-specific protease that modifies IGFBP-4 structure and function, and indicate a preferential role for IGF-II in its activation. Posttranslational regulation of IGFBP-4 may provide a means for cooperative control of local cell growth by IGF-I and IGF-II.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680662      PMCID: PMC288069          DOI: 10.1172/JCI116272

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

Review 1.  Insulin-like growth factor receptors.

Authors:  P Nissley; W Lopaczynski
Journal:  Growth Factors       Date:  1991       Impact factor: 2.511

2.  Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150K complex during pregnancy.

Authors:  P Hossenlopp; B Segovia; C Lassarre; M Roghani; M Bredon; M Binoux
Journal:  J Clin Endocrinol Metab       Date:  1990-10       Impact factor: 5.958

3.  Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity.

Authors:  L C Giudice; E M Farrell; H Pham; G Lamson; R G Rosenfeld
Journal:  J Clin Endocrinol Metab       Date:  1990-10       Impact factor: 5.958

4.  Discrete alterations of the insulin-like growth factor I molecule which alter its affinity for insulin-like growth factor-binding proteins result in changes in bioactivity.

Authors:  D R Clemmons; M A Cascieri; C Camacho-Hubner; R H McCusker; M L Bayne
Journal:  J Biol Chem       Date:  1990-07-25       Impact factor: 5.157

5.  An inhibitory insulin-like growth factor binding protein (In-IGFBP) from human prostatic cell conditioned medium reveals N-terminal sequence identity with bone derived In-IGFBP.

Authors:  V S Perkel; S Mohan; D J Baylink; T A Linkhart
Journal:  J Clin Endocrinol Metab       Date:  1990-08       Impact factor: 5.958

6.  Basal and regulated secretion of insulin-like growth factor binding proteins in osteoblast-like cells is cell line specific.

Authors:  C Hassager; L A Fitzpatrick; E M Spencer; B L Riggs; C A Conover
Journal:  J Clin Endocrinol Metab       Date:  1992-07       Impact factor: 5.958

7.  Cyclic changes in insulin-like growth factor-binding protein-4 messenger ribonucleic acid in the rat ovary.

Authors:  G F Erickson; A Nakatani; N Ling; S Shimasaki
Journal:  Endocrinology       Date:  1992-02       Impact factor: 4.736

8.  Regulation of insulin-like growth factor binding protein-3 messenger ribonucleic acid expression by insulin-like growth factor I.

Authors:  L K Bale; C A Conover
Journal:  Endocrinology       Date:  1992-08       Impact factor: 4.736

9.  Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex.

Authors:  P G Campbell; J F Novak; T B Yanosick; J H McMaster
Journal:  Endocrinology       Date:  1992-03       Impact factor: 4.736

10.  Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanism.

Authors:  C A Conover
Journal:  Endocrinology       Date:  1992-06       Impact factor: 4.736

View more
  22 in total

Review 1.  Implications of the PAPP-A-IGFBP-IGF-1 pathway in the pathogenesis and treatment of polycystic kidney disease.

Authors:  Sonu Kashyap; Julianna D Zeidler; Claudia C S Chini; Eduardo Nunes Chini
Journal:  Cell Signal       Date:  2020-06-20       Impact factor: 4.315

Review 2.  B lymphopoiesis: global factors, local control.

Authors:  P W Kincade
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

3.  Blocking ligand occupancy of the alphaVbeta3 integrin inhibits insulin-like growth factor I signaling in vascular smooth muscle cells.

Authors:  B Zheng; D R Clemmons
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

4.  Mutational analysis of the proteolytic domain of pregnancy-associated plasma protein-A (PAPP-A): classification as a metzincin.

Authors:  H B Boldt; M T Overgaard; L S Laursen; K Weyer; L Sottrup-Jensen; C Oxvig
Journal:  Biochem J       Date:  2001-09-01       Impact factor: 3.857

Review 5.  PAPP-A: a new anti-aging target?

Authors:  Cheryl A Conover
Journal:  Aging Cell       Date:  2010-10-21       Impact factor: 9.304

6.  The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A.

Authors:  J B Lawrence; C Oxvig; M T Overgaard; L Sottrup-Jensen; G J Gleich; L G Hays; J R Yates; C A Conover
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

7.  Transforming growth factor-beta1 modulates insulin-like growth factor binding protein-4 expression and proteolysis in cultured periosteal explants.

Authors:  Carlos Gonzalez; Kiem G Auw Yang; Joseph H Schwab; James S Fitzsimmons; Monica M Reinholz; Zachary T Resch; Laurie K Bale; Victoria R Clemens; Cheryl A Conover; Shawn W O'Driscoll; Gregory G Reinholz
Journal:  Growth Horm IGF Res       Date:  2009-08-04       Impact factor: 2.372

8.  In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells.

Authors:  C Blat; J Villaudy; M Binoux
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

9.  Expression of insulin-like growth factor binding proteins by T-47D human breast cancer cells: regulation by progestins and antiestrogens.

Authors:  A Coutts; L J Murphy; L C Murphy
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

10.  Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer.

Authors:  A J Ryan; S Napoletano; P A Fitzpatrick; C A Currid; N C O'Sullivan; J H Harmey
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.